AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.
Building a stream of dividends to fatten your wallet every quarter is a lot easier when you're willing to play the long game. AbbVie (NYSE: ABBV) is a passive-income machine, and this is all thanks to its ability to churn out therapies at an industrial scale. Strong earnings growth is likely to continue in the long run -- after a short delay, that is.
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.